← Leaderboards
Umut A. Gurkan
Case Western Reserve University
$6,831,209
Attributed
$11,091,496
Total exposure
9
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2016–25$5M$3.8M$2.5M$1.3M$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,091,496 · 9
By mechanism
R42$4,395,940 · 3
R01$1,983,380 · 1
OT2$1,907,734 · 1
U01$1,431,363 · 1
R56$663,187 · 1
R21$413,972 · 1
Top collaborators
- Chiara Federici9 shared
- Jane Little5 shared
- Petros Giannikopoulos3 shared
- Peter Galen1 shared
- Aaron Weinberg1 shared
Most similar at Case Western Reserve University
Same institution · by research overlap
- Jane Little$1,245,366
- Scott Frederick Sieg$6,670,247
- Ge Jin$9,062,600
- Thomas S McCormick$4,069,015
- Ran An$425,944
Others in their field
Top investigators on “Sickle Cell Anemia”
- Russell E Ware · Duke University$48,435,687
- Michael Rutledge Debaun · Vanderbilt University Medical Center$38,268,866
- Martin H. Steinberg · Boston Medical Center$25,628,557
- Michael L. Terrin · Clinical Trials And Surveys Corporation$23,855,067
- Barbara L Kroner · Research Triangle Institute$21,141,016
- Garret A Fitzgerald · University Of Pennsylvania$20,602,198
Research focus
Sickle Cell AnemiaErythrocytesMicrofluidicsPainValidationMortalityPropertyMorbidity - Disease RateCell AdhesionHemoglobinStandardizationAbnormal Red Blood CellPharmaceutical PreparationsMonitorInheritedHematological DiseaseResponseSicklingAdhesivesDevicesSickle HemoglobinFunctional DisorderGene TherapyBlood Vessels
Grant awards (23)
A Modality-Agnostic Potency Assay Enabling Both Ex Vivo and In Vivo Genome Editing Therapeutics for Sickle Cell Disease$470,454
U01 · FY2025 · AI
Manufacturing and Analytical Validation of the Microfluidic Impedance Red Cell Assay (MIRCA) for Commercial Viability$312,371
R42 · FY2025 · HL
Microfluidic Technology for Concurrent Assessment of Red Blood Cell Adhesion and Deformability$865,375
R42 · FY2024 · HL
A Modality-Agnostic Potency Assay Enabling Both Ex Vivo and In Vivo Genome Editing Therapeutics for Sickle Cell Disease$471,367
U01 · FY2024 · AI
RHODA: Rapid Hemoglobin-Oxygen Dissociation Assay$295,920
R41 · FY2024 · HL
Microfluidic Technology for Concurrent Assessment of Red Blood Cell Adhesion and Deformability (Administrative Supplement)$70,840
R42 · FY2024 · HL
Microfluidic Technology for Concurrent Assessment of Red Blood Cell Adhesion and Deformability$865,376
R42 · FY2023 · HL
Endothelialized microfluidic assays for emerging therapies in sickle cell disease$842,828
R42 · FY2023 · HL
A Modality-Agnostic Potency Assay Enabling Both Ex Vivo and In Vivo Genome Editing Therapeutics for Sickle Cell Disease$489,542
U01 · FY2023 · AI
Microfluidic Technology for Concurrent Assessment of Red Blood Cell Adhesion and Deformability$70,840
R42 · FY2023 · HL
Endothelialized microfluidic assays for emerging therapies in sickle cell disease$852,121
R42 · FY2022 · HL
Microfluidic Impedance Red Cell Assay (MIRCA) for Emerging Pharmacologic and Gene based Therapies for Sickle Cell Disease$663,187
R56 · FY2022 · HL · contact PI
Microfluidic Technology for Concurrent Assessment of Red Blood Cell Adhesion and Deformability$259,611
R42 · FY2022 · HL
Endothelialized microfluidic assays for emerging therapies in sickle cell disease$256,578
R42 · FY2021 · HL
Clinical Microfluidic Assessment of Red Blood Cell Adhesion, Deformability, Cellular Hemoglobin Distribution, Cellular Density, and Blood Rheology for Curative Therapies in Sickle Cell Disease$29,717
OT2 · FY2021 · HL · contact PI
Clinical Microfluidic Assessment of Red Blood Cell Adhesion, Deformability, Cellular Hemoglobin Distribution, Cellular Density, and Blood Rheology for Curative Therapies in Sickle Cell Disease$1,799,428
OT2 · FY2020 · HL · contact PI
Microfluidic intact cell platform: A novel tool for oral cancer detection$413,972
R21 · FY2020 · CA
Standardized Monitoring of Cellular Adhesion to Improve Clinical Care in Sickle Cell Disease$393,231
R01 · FY2020 · HL · contact PI
Standardized Monitoring of Cellular Adhesion to Improve Clinical Care in Sickle Cell Disease$393,501
R01 · FY2019 · HL · contact PI
Clinical Microfluidic Assessment of Red Blood Cell Adhesion, Deformability, Cellular Hemoglobin Distribution, Cellular Density, and Blood Rheology for Curative Therapies in Sickle Cell Disease$78,589
OT2 · FY2019 · HL · contact PI
Standardized Monitoring of Cellular Adhesion to Improve Clinical Care in Sickle Cell Disease$393,761
R01 · FY2018 · HL · contact PI
Standardized Monitoring of Cellular Adhesion to Improve Clinical Care in Sickle Cell Disease$394,010
R01 · FY2017 · HL
Standardized Monitoring of Cellular Adhesion to Improve Clinical Care in Sickle Cell Disease$408,877
R01 · FY2016 · HL